Table 2

Glycaemia-related outcomes in the intervention and control arms of the EMmY trial

Outcomes (unit) (intervention;control)*Intervention
(myo-inositol)
Mean (SD)
Control
(placebo)
mean (SD)
MD
(95% CI)
OGTT fasting (mmol/L) (81; 81)4.5 (0.5)4.6 (0.4)−0.0 (−0.2 to 0.1)
OGTT 2 hours (mmol/L) (80; 81)6.1 (2)6.0 (1.3)0.0 (−0.5 to 0.6)
HOMA-IR (50; 62)2.13 (1.32)2.8 (2.05)0.6 (−1.2 to 0.0)
Insulin (mlU/L) (53; 63)10.63 (6.11)13.72 (8.89) −2.69 (−5.26 to −0.18)
Leptin (μg/L) (53; 63)42.7 (21.6)38.3 (17.1)4.4 (−2.7 to 11.4)
Adiponectin (mg/L) (53; 63)6.6 (3.5)6.1 (3.8)0.5 (−0.9 to 1.8)
Urinary inositol (mg/L) (53; 65)265.7 (209.7)194.7 (118.7)70.76 (11.2 to 130.8)
c-peptide (μg/L) (53; 63)1538.5 (679.6)1804.3 (807.8)−253.6 (−522.7 to 10.4)
c-peptide in cord blood (μg/L) (10; 6)457 (268.04)535 (296.02)−101.74 (−358.17 to 202.17)
  • *Number of women in the intervention and control group, respectively.

  • †Values in bold specifically described within secondary outcomes results.

  • HOMA-IR, homoeostatic model assessment-insulin resistance; MD, mean difference; OGTT, oral glucose tolerance test.